Association of ADIPOR2 gene variants with cardiovascular disease and type 2 diabetes risk in individuals with impaired glucose tolerance: the Finnish Diabetes Prevention Study by Siitonen, Niina et al.
ORIGINAL INVESTIGATION Open Access
Association of ADIPOR2 gene variants with
cardiovascular disease and type 2 diabetes risk in
individuals with impaired glucose tolerance: the
Finnish Diabetes Prevention Study
Niina Siitonen
1*, Leena Pulkkinen
1, Jaana Lindström
2,3, Marjukka Kolehmainen
1, Ursula Schwab
1,4,
Johan G Eriksson
2,5,6,7,8, Pirjo Ilanne-Parikka
9,10, Sirkka Keinänen-Kiukaanniemi
11,12,13, Jaakko Tuomilehto
2,3,14,15 and
Matti Uusitupa
1,16
Abstract
Background: Adiponectin is an adipokine with insulin-sensitising and anti-atherogenic effects. Two receptors for
adiponectin, ADIPOR1 and ADIPOR2, have been characterized that mediate effects of adiponectin in various tissues.
We examined whether genetic variation in ADIPOR2 predicts the development of cardiovascular disease (CVD) and/
or Type 2 Diabetes (T2DM) in individuals with impaired glucose tolerance (IGT) participating the Finnish Diabetes
Prevention Study (DPS).
Methods: CVD morbidity and mortality data were collected during a median follow-up of 10.2 years (range 1-13
years) and conversion from IGT to T2DM was assessed during a median follow-up of 7 years (range 1-11 years).
Altogether eight SNPs in the ADIPOR2 locus were genotyped in 484 participants of the DPS. Moreover, the same
SNPs were genotyped and the mRNA expression levels of ADIPOR2 were determined in peripheral blood
mononuclear cells and subcutaneous adipose tissue samples derived from 56 individuals participating in the
Genobin study.
Results: In the DPS population, four SNPs (rs10848554, rs11061937, rs1058322, rs16928751) were associated with
CVD risk, and two remained significant (p = 0.014 for rs11061937 and p = 0.020 for rs1058322) when all four were
included in the same multi-SNP model. Furthermore, the individuals homozygous for the rare minor alleles of
rs11061946 and rs11061973 had increased risk of converting from IGT to T2DM. Allele-specific differences in the
mRNA expression levels for the rs1058322 variant were seen in peripheral blood mononuclear cells derived from
participants of the Genobin study.
Conclusions: Our results suggest that SNPs in the ADIPOR2 may modify the risk of CVD in individuals with IGT,
possibly through alterations in the mRNA expression levels. In addition an independent genetic signal in ADIPOR2
locus may have an impact on the risk of developing T2DM in individuals with IGT.
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Adipose tissue (AT) secretes a number of bioactive
molecules, called adipokines, which participate in regu-
lation of various metabolic processes [1]. Excess adipos-
ity, particularly central type of adiposity, is associated
with chronic low grade inflammation and dysregulated
production of adipokines with adverse metabolic conse-
quences, such as insulin resistance, hypertension, dysli-
pidemia, and increased risk of cardiovascular disease
(CVD) [1].
Adiponectin is an adipokine with insulin-sensitising,
anti-inflammatory and anti-atherogenic properties [2-7].
Circulating levels of adiponectin are decreased in obesity
[8], dyslipidemia [9], cardiovascular disease (CVD) [10],
insulin resistance and T2DM [8]. The insulin-sensitising
effects of adiponectin involve stimulation of fatty acid
oxidation and glucose uptake in skeletal muscle and
suppression of gluconeogenesis in liver [5]. The anti-
atherogenic effects of adiponectin include suppression of
adhesion molecule expression on vascular endothelial
cells [6], and inhibition of vascular smooth muscle cell
proliferation and migration [7]. Adiponectin also stimu-
lates the production of NO in endothelial cells [11] and
reduces atherosclerosis by suppressing endothelial
inflammatory reaction and macrophage to foam cell
transformation [2].
Two adiponectin receptors, ADIPOR1 and ADIPOR2,
have been characterized that mediate the functions of
adiponectin through activation of 5’ AMP-activated pro-
tein kinase (AMPK) and peroxisome proliferator-acti-
vated receptor alpha (PPARa)[ 1 2 ] .I nm i c e ,AdipoR2 is
mostly expressed in liver, while AdipoR1 is ubiquitously
expressed [12]. Mice deficient for either or both recep-
tors were glucose intolerant, and adenovirus mediated
expression of AdipoR1 and AdipoR2 in liver improved
obesity-related insulin resistance and T2DM in db/db
mice through AMPK and PPARa pathways, respectively
[13]. In contrast, Bjursel et al. reported that AdipoR2-
KO mice were lean and resistant to high fat diet
induced weight gain, had improved glucose tolerance
and decreased plasma total and HDL cholesterol levels
[14]. In humans, ADIPOR2 is highly expressed in skele-
tal muscle and correlates positively with insulin sensitiv-
ity [15] and fasting plasma triglyceride concentrations in
healthy glucose tolerant subjects [16]. On the contrary,
the expression level of ADIPOR2,b u tn o tADIPOR1,
was decreased in the intra-abdominal AT of obese indi-
viduals, and correlated negatively with triglyceride and
apolipoprotein B levels [17]
ADIPOR2 gene is located on chromosomal locus
12p13.33 and consists of nine exons. Associations
between ADIPOR2 gene variants with insulin resistance
and T2DM related phenotypes [18-21], triglyceride
levels [22-24], liver fat content [24,25], and CAD [26]
have been reported in several human populations. Other
studies have, however, failed to detect associations
between ADIPOR2 variants and T2DM [27-29] or other
metabolic parameters [30,31]. The differences may be
attributed to different characteristics of study partici-
pants or differences in study designs.
Most previous studies investigating the role of ADI-
POR2 variants in T2DM and related phenotypes have
been cross-sectional, and therefore have not been able
to evaluate the effect of ADIPOR2 variants in the devel-
opment of T2DM. The aim of this study was to investi-
gate the role of ADIPOR2 locus variation in individuals
with impaired glucose tolerance (IGT) participating in a
controlled lifestyle intervention study (DPS study) with
longitudinal data on metabolic and anthropometric
parameters, and CVD incidence. In addition, we ana-
lysed whether ADIPOR2 variants were associated with
the mRNA expression levels in PBMCs and subcuta-
neous AT samples derived from individuals with meta-
bolic syndrome.
Methods
DPS population and study design
DPS is a randomised, controlled multicentre study with
five participating study clinics in Finland. The main aim
of DPS was to assess the efficacy of lifestyle modification
on preventing or delaying the onset of T2DM in indivi-
duals with IGT. The diagnosis of IGT and T2DM were
based on WHO 1985 criteria [32]. IGT (fasting plasma
glucose < 7.8 mmol/l and a 2-h plasma glucose 7.8-11.0
mmol/l) was based on the mean value of two oral glu-
cose tolerance tests (OGTT) and diagnosis of T2DM
w a sc o n f i r m e db yas e c o n dO G T T[ 3 3 ] .T h es t u d y
design has been described earlier in detail [33,34]. Alto-
gether 522 overweight (BMI≥25 kg/m
2)v o l u n t e e r sa g e d
40-64 years were randomly allocated into an intensive
diet and exercise intervention group or a control group.
The individuals in the intervention group received indi-
vidualized diet and exercise counseling, whereas indivi-
duals in the control group were given general
information on healthy diet and exercise [35]. The med-
ian length of the intervention period was four years
(range 1-6 year).
Clinical and biochemical analyses in DPS
At baseline and annually, a medical history was recorded
and physical examination with anthropometric measure-
ments performed on each study participant. In addition,
a 2-hour OGTT was performed annually with glucose a
load of 75 g. Plasma glucose was measured locally by
standard methods as previously described [35]. Serum
insulin was measured by RIA (Phadaseph Insulin RIA
100, Pharmacia Diagnostica, Uppsala, Sweden). The
intra-assay coefficient of variation was 5.3% and the
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tions of serum total and HDL cholesterol, and serum
triglycerides were determined annually from fasting
samples by using an enzymatic assay method in central
laboratory in Helsinki. LDL cholesterol concentrations
were calculated by using the Friedewald formula.
Mortality and cardiovascular morbidity data were col-
lected after a median 10.2 years (range 1-13 years) fol-
low-up of from the national Hospital Discharge Register
and Causes of Death Register using the unique personal
identification number [36]. The end-points during fol-
low-up were total mortality, and incident cardiovascular
events (fatal and non-fatal), including acute coronary
events, coronary heart disease, stroke and hypertensive
disease.
Frozen serum samples for adiponectin measurements
were only available from a subset of participants from
three study clinics at baseline (n = 243). Fasting serum
adiponectin levels were measured using an enzyme-
linked immunosorbent assay (ELISA) (B-Bridge Interna-
tional, Inc., San Jose, CA, USA), on whole plasma stored
at -80°C. The intra-assay and inter-assay coefficients of
variation were 5.5-7.9% and 6.5%, respectively.
The study protocol was approved by the Ethics Com-
mittee of the National Public Health Institute in Hel-
sinki, Finland. Written informed consent was received
from all participants [33,34]. We certify that all applic-
able institutional and governmental regulations concern-
ing the ethical use of human volunteers were followed
during this study.
Genobin study population and study design
Seventy-five overweight or obese (BMI 28-40 kg/m
2)
men and women (aged 40-70 years) were recruited to
the study. The subjects had impaired fasting glycemia
(IFG: fasting plasma glucose concentration 5.6-7.0
mmol/l), or IGT (2-h plasma glucose concentration 7.8-
11.0 mmol/l and fasting plasma glucose <7.1 mmol/l),
and fulfilled at least two criteria of the metabolic syn-
drome according to the Adult Treatment Panel III Cri-
teria [37] as modified by the American heart
Association [38]: waist circumference >102 cm for men
and >88 cm for women; fasting serum triacylglycerol
≥1.7 mmol/l; fasting serum HDL cholesterol <1.0 mmol/
l for men and <1.3 for women; blood pressure ≥130/80
mmHg. The Ethics Committee of the District Hospital
Region of Northern Savo approved the study plan. All
participants volunteered fort h es t u d ya n dg a v et h e i r
written informed consent.
Analysis of gene expression from PBMCs and AT samples
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from anticoagulated peripheral blood, collected at
baseline, by using Lymphoprepr e a g e n t( A x i s - S h i e l d ,
Oslo, Norway). A needle biopsy was taken after an over-
night fast from subcutaneous abdominal AT under local
anesthesia (Lidocaine 10 mg/ml without epinephrine) at
baseline. The AT samples for the RNA extraction were
treated with RNA later according to instructions pro-
vided by manufacturer (Ambion, Austi, TX, USA) and
stored at -80°C.
Altogether 56 baseline PBMC and AT samples were
available. Total RNA was extracted using an RNeasy
Mini Kit (Qiagen, Valencia, CA, USA) according to the
instructions of manufacturers. RNA was reverse tran-
scribed into cDNA by using High-Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA, USA).
RNA concentration and A260/A280 ratio were measured
using NanoDrop spectrophotometer (Nanodrop Tech-
nologies, Wilmington, DE) with acceptable ratio being
1.9-2.1 Integrity of RNA sample was assessed using
agarose gel electrophoresis.
Real-time PCR was performed with ready-made assays
b a s e do nT a q M a nc h e m i s t r ya n da n a l y s e dw i t hA B I
Prism 7500 SDS software (Applied Biosystems). All sam-
ples were analysed as triplicates and each reaction con-
sisted of 6 ng cDNA, 1X Assay Mix, and 1X Taqman
Universal PCR Master Mix (Applied Biosystems). The
relative quantity of cDNA in each sample was assessed
by using the methods described in ABI Prism User Bul-
letin no. 2. Briefly, on each plate, a standard curve with
five known cDNA concentrations (0.5, 1.5, 6, 18, and 36
ng/μl) and a calibrator (6 ng/μl) were included. The
cDNA quantity of each sample was determined by com-
paring it to the standard curve and the relative quantity
was calculated by dividing it with the quantity of cali-
brator. Finally, the relative expression quantity on each
plate was normalised to the expression levels of an
endogenous control gene, which was glyceraldehydes-3-
phosphate dehydrogenase for the PBMCs and cyclophilin
A1 for the AT samples.
Selection of SNPs and genotyping
DNA samples were available from 484 DPS participants
(160 men and 324 women) and 56 Genobin participants
(29 men and 27 women). Tagging SNPs were selected
based on genotype data of the Hapmap CEU (Utah resi-
dents with ancestry from Northern and Western Eur-
ope) population [39] by using the Tagger algorithm
[40]. The eight SNPs selected for genotyping in DPS
captured 63% (60 of 94) of common variants in the
ADIPOR2 locus with r
2 ≥ 0.8. All SNPs were genotyped
with TaqMan Allelic Discrimination assays according to
manufacturer’si n s t r u c t i o n sb yu s i n gt h eA B IP R I S M
7000 sequence detector (Applied Biosystems, Foster
City, CA). For a subset of randomly selected samples
(6.3%) genotyping was repeated in order to calculate
success rate.
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Statistical tests were performed using the SPSS statistical
software for Windows (version 14.0, SPSS Inc., Chigago,
IL, USA). The pairwise linkage disequilibrium (LD)
between SNPs in DPS was evaluated with Haploview
software (version 4.2; Broad institute, Cambridge, MA)
[41].
The Hardy-Weinberg equilibrium (HWE) and geno-
type distributions among study groups were analysed
using Chi-square test. The normality of distributions
of the continuous variables was checked with the Kol-
mogorov-Smirnov test with Lilliefors correction and
variable transformations were applied when appropri-
ate. Genetic analyses were carried out using additive
( a l lt h r e eg e n o t y p eg r o u p sw e r ec o m p a r e d )o rd o m i -
nant (common allele homozygotes were compared
with the minor allele carriers) inheritance models.
Using appropriate adjustments, the genotype differ-
ences in continuous variables were analysed with gen-
eral linear model (GLM) univariate analysis of variance
(ANOVA). Normality was assessed by plotting the
residuals.
The association of ADIPOR2 SNPs with cardiovascular
risk was analysed with Cox regression model adjusting
for age, sex, baseline waist circumference, study group,
CVD history at baseline, systolic blood pressure smoking
status, and total-to-HDL cholesterol ratio at baseline in
467 DPS participants for whom CVD data and the rele-
vant covariates were available. Likewise, in 482 partici-
pants for whom all relevant variables were available the
association of the ADIPOR2 SNPs with conversion to
T2DM was analysed by using Cox regression adjusting
for age, sex, waist circumference, study group, and
either fasting or 2-hour plasma glucose.
Multiple hypothesis testing is a general problem in
genetic association studies and increases the likelihood
of false positive findings. In order to control for multiple
t e s t i n g ,w eu s e dt h ef a l s ed i s c o v e r yr a t e( F D R )m e t h o d
with the Q value 1.0 software [42] for single SNP ana-
lyses and provide q-values in combination with p-values
to help in the interpretation of the results. The q-values
were calculated separately for each trait, but all SNPs
and both inheritance models were included in the same
calculations. Level of statistical significance was set to p
< 0.05, and the q-values of q < 0.150 were considered as
additional proof for true associations.
Results
Baseline characteristics and genotype frequencies
Table 1 shows the clinical and metabolic baseline char-
acteristics for both study populations. Eight ADIPOR2
SNPs were genotyped from the DNA samples of 484
DPS and 56 Genobin participants with an error rate of
0% and a call rate of 100% in replicated samples for all
markers. Genotype counts and minor allele frequencies
are reported in table 2 and the pairwise LD measures in
the DPS population are presented in table 3. All SNPs,
except rs11061946 in the DPS, were in Hardy-Weinberg
equilibrium (HWE, p > 0.05). However, we included this
SNP in further analyses, since the q-value was high (q >
0.150) and the deviation from HWE was likely a chance
finding resulting from small minor allele frequency
(MAF). Two SNPs (rs11061946 and rs11061973)
demonstrated differential genotype frequencies in the
DPS study groups according to p-value (p < 0.05), but
not according to q-value (q > 0.150). We included these
SNPs in all analyses, but performed all analyses con-
cerning the follow-up data separately in both groups.
Table 1 Baseline characteristics of the DPS and Genobin study participants
DPS Genobin
Males (n)/Females (n) 160/324 29/27
Age (y) 55.2 ± 7.0 (484) 59.4 ± 6.8 (56)
Weight (kg) 86.3 ± 14.2 (484) 92.8 ± 14.0 (56)
BMI (kg/m
2) 31.2 ± 4.5 (484) 32.7 ± 2.9 (56)
Waist circumference (cm) 101.2 ± 11.0 (482) 108.9 ± 8.9 (56)
Fasting plasma glucose (mmol/L) 6.13 ± 0.75 (484) 6.44 ± 0.49 (56)
2-h plasma glucose (mmol/L) 8.88 ± 1.49 (484) 7.42 ± 2.15 (56)
Fasting serum insulin (mU/L) 14.73 ± 7.46 (439) 11.96 ± 7.29 (56)
2-h serum insulin (mU/L) 95.57 ± 65.83 (436) 83.38 ± 72.92 (56)
Serum total cholesterol (mmol/L) 5.61 ± 0.93 (483) 5.16 ± 0.98 (56)
Serum HDL cholesterol (mmol/L) 1.21 ± 0.29 (483) 1.23 ± 0.22 (56)
Serum LDL cholesterol (mmol/L) 3.62 ± 0.84 (481) 3.37 ± 0.91 (56)
Serum triglycerides (mmol/l) 1.73 ± 0.78 (483) 1.66 ± 0.84 (56)
Diastolic blood pressure (mmHg) 86 ± 10 (479) 89 ± 10 (56)
Systolic blod pressure (mmHg) 138 ± 17 (479) 136 ± 14 (56)
Data are mean ±SD
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After a median follow-up period of 10.2 years, there
were 100 CVD events among the DPS participants
included in these analyses (50/241 in the intervention
and 50/232 in the control group) [36]. Of the eight
ADIPOR2 SNPs included in the analyses, differences in
the CVD risk were seen according to four SNPs (table
4 and figure 1 for rs1058322). The rs10848554 C allele
was associated with an increased risk of CVD when
compared with the GG genotype (p = 0.048/q =
0.095). Moreover, individuals carrying the rs11061937
C allele had significantly lower risk of CVD events
compared with those with the TT genotype (p =
0.013/q = 0.095). When all three genotypes were com-
pared, the risk was lower for individuals with the TC
genotype compared with those with the TT genotype
(p = 0.012/q = 0.095). Finally, the rs1058322 T allele
and the rs16928751 A allele were dose-dependently
associated with higher risk of CVD (p = 0.014/q =
0.095 and p = 0.015/q = 0.095, respectively for the
dominant inheritance model). Although significant
study group-SNP interaction was not observed for any
of the SNPs, we performed all analyses separately in
both study groups and found similar results in both
(data not shown). Moreover, we did not find significant
interaction between ADIPOR2 variants and sex or
baseline BMI on CVD risk.
In a multiple SNP-model, including all four SNPs that
individually were associated with CVD risk, two variants
(rs11061937 and rs1058322) remained significant predic-
tors of CVD risk (p = 0.016 and p = 0.023, respectively).
Table 2 Genotype counts and allele frequencies of ADIPOR2 SNPs in the DPS and Genobin study population
SNP and its location within gene HWE
Population Genotype counts MAF p/q
a p/q
b
rs10848554 GG GC CC C
5’ promoter region DPS 373 104 7 0.122 0.934/0.389 0.401/0.204
Genobin 44 12 0 0.107 0.369/0.377
rs11061937 TT TC CC C
Intron 1 DPS 213 214 57 0.339 0.772/0.378 0.208/0.170
Genobin 16 27 13 0.473 0.805/0.378
rs11061946 CC CT TT T
Intron 1 DPS 430 49 5 0.061 0.011/0.377 0.042/0.170
Genobin 48 8 0 0.071 0.565/0.377
rs1058322 CC CT TT T
Intron 1 DPS 230 206 48 0.320 0.850/0.378 0.958/0.299
Genobin 22 29 5 0.348 0.292/0.377
rs11061973 GG GA AA A
Intron 2 DPS 403 76 5 0.089 0.508/0.377 0.027/0.170
Genobin 44 12 0 0.107 0.369/0.377
rs4766415 AA AT TT T
Intron 2 DPS 128 254 102 0.473 0.247/0.377 0.243/0.170
Genobin 11 26 19 0.429 0.697/0.378
rs16928751 GG GA AA A
Exon 7 DPS 379 101 4 0.113 0.331/0.377 0.493/0.206
Genobin 47 9 0 0.080 0.513/0.377
rs1044471 CC CT TT T
3’ UTR DPS 136 245 103 0.466 0.706/0.378 0.578/0.207
Genobin 22 28 6 0.357 0.506/0.377
ap/q value for Hardy-Weinberg equilibrium;
bp/q value for differences in genotype frequencies between the study groups of DPS; Correction for multiple
hypothesis testing was performed with FDR, denoted as q-value.
Table 3 Pairwise linkage disequilibrium measures of the
ADIPOR2 SNPs in the DPS population
SNP1 SNP2 SNP3 SNP4 SNP5 SNP6 SNP7 SNP8
SNP1 1.0 0.483 0.971 1.0 1.0 1.0 1.0
SNP2 0.071 1.0 0.101 0.977 0.955 1.0 0.945
SNP3 0.0020 0.125 0.291 1.0 1.0 0.314 1.0
SNP4 0.291 0.0090 0.012 0.094 0.637 0.984 0.569
SNP5 0.013 0.178 0.674 0.0020 1.0 0.912 1.0
SNP6 0.155 0.525 0.072 0.204 0.107 1.0 0.922
SNP7 0.918 0.065 0.0010 0.275 0.01 0.143 1.0
SNP8 0.121 0.401 0.056 0.127 0.083 0.663 0.111
SNP1, rs10848554; SNP2 rs11061937; SNP3, rs11061946; SNP4, rs1058322;
SNP5, rs11061973; SNP6, rs4766415; SNP7, rs16928751; SNP8, rs1044471; D’
(above empty cells) and r
2 (below empty cells)
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In a subgroup of DPS participants whose serum adipo-
nectin levels were measured at baseline, we analysed
whether circulating adiponectin levels predict future risk
of CVD. A trend for lower CVD risk was seen in those
with higher than the median (6.250 for men and 8.815
for women) serum adiponectin levels, compared with
those with adiponectin below the median (HRR 0.564,
95% CI 0.312-1.019, p = 0.058).
The risk of T2DM
During the median follow-up of 7 years (range 1-11
years), the number of new T2DM cases among the
DPS participants included in these analyses was 175
(71/245 in the intervention group and 104/239 in the
control group) [43]. Subjects homozygous for
rs11061946 and rs11061973 minor alleles (n = 5), had
significantly higher risk of T2DM compared with sub-
jects homozygous for the major alleles of these SNPs
when adjusted for age, sex, study group, baseline waist
circumference, and either fasting or 2-h glucose levels.
The results are presented in table 5 for model adjusted
with 2-h glucose levels, but the results were essentially
similar when the model was adjusted for fasting
plasma glucose instead. When the dominant inheri-
tance model was used, no genotype differences in risk
of T2DM were observed. When study groups were
analyzed separately, results were similar in both study
groups (data not shown).
ADIPOR2 mRNA expression in the Genobin study
population
The ADIPOR2 mRNA expression in the PBMCs differed
according to rs1058322 genotype (figure 2) at baseline (p
= 0.029/q = 0.328 for the dominant inheritance model
adjusted for age, sex and baseline BMI). Individuals car-
rying the T allele had lower expression levels compared
with those with the CC genotype. Other SNPs in ADI-
POR2 did not associate with mRNA expression levels in
PBMCs and differences in expression levels according to
ADIPOR2 SNPs were not observed in AT.
Discussion
The results of the present study suggest that indepen-
dent genetic signals in the ADIPOR2 locus contribute to
t h er i s ko fC V Da n dT 2 D Mi nas t u d yp o p u l a t i o nc o n -
sisting of individuals with impaired glucose tolerance.
Of the eight SNPs analysed in DPS study population,
rs10848554, rs11061937, rs1058322 and rs16928751
associated with the risk of CVD during the median
Table 4 Hazard ratios for the significant association between ADIPOR2 SNPs and the development of CVD during
follow-up of median 10.2 years
HR (95% CI), p/q
a HR, 95% CI, p/q
b
rs10848554 GG (358) 1 1
GC (102) 1.510 (0.957-2.382), 0.076/0.110 1.565 (1.004-2.440), 0.048/0.095
CC (7) 2.919 (0.697-12.23), 0.143/0.150
rs11061937 TT (207) 1 1
TC (206) 0.568 (0.364-0.885), 0.012/0.095 0.595 (0.395-0.896), 0.013/0.095
CC (54) 0.701 (0.353-1.390), 0.309/0.238
rs1058322 CC (218) 1 1
CT (201) 1.601 (1.021-2.509), 0.040/0.095 1.711 (1.114-2.627), 0.014/0.095
TT (48) 2.300 (1.194-4.433), 0.013/0.095
rs16928751 GG (364) 1 1
GA (99) 1.677 (1.051-2.674), 0.030/0.095 1.756 (1.114-2.766), 0.015/0.095
AA (4) 4.425 (1.042-18.79), 0.044/0.095
All analyses were adjusted for age, sex, baseline waist circumference, baseline 2-h plasma glucose and study group; Correction for multiple hypothesis testing in
single SNP analyses was performed by using FDR, denoted as q-value;
aAdditive inheritance model for single SNP analyses;
bDominant inheritance model for
single SNP analyses.
Figure 1 Survival curve for CVD incidence according to
ADIPOR2 rs1058322 in DPS participants. Additive inheritance
model, adjusted for age, sex, baseline waist circumference, study
group, CVD at baseline, systolic blood pressure, smoking status, and
baseline total-to-HDL cholesterol ratio.
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included in the same model only rs11061937 and
rs1058322 remained significant predictors of CVD, indi-
cating independent effects of these two variants. This is
supported also by the observation that these SNPs
demonstrated a weak pairwise LD with each other. The
rs11061937 was in low LD (r
2 ranging from 0.0090 to
0.071) with the other three SNPs, whereas rs1058322
was in moderate LD with rs10848554 (r
2 =0 . 2 9 1 )a n d
rs16928751 (r
2 = 0.275), and rs10848554 and
rs16928751 were in high LD with each other (r
2 =
0.918).
The rs16928751 variant has been previously found to
be associated with plasma adiponectin and fasting trigly-
cerides levels in a small study population of individuals
with the metabolic syndrome [22], and T2DM in a case-
control study [18]. Recently the association of an intro-
nic variant, rs767870, with coronary artery disease,
intima media thickness and endothelial dysfunction was
reported in a cross-sectional study population [26]. This
variant also associated with fasting plasma triglyceride
concentrations, along with 13 other ADIPOR2 SNPs, in
Mexican American subjects [23], and in a population
based sample of 3050 Finnish subjects [24]. Moreover,
rs767870 has been associated with measures of liver fat
content and its surrogate markers [24], and T2DM in a
case-control study of 1498 Caucasian subjects [20].
Unfortunately, rs767870 was not genotyped in our study
population. However, in the HapMap CEU population,
rs767870 is in high or moderate LD with three SNPs
that associated with CVD risk in DPS: rs10848554 (r
2 =
0.774 and D’ = 0.916), rs1058322 (r
2 =0 . 3 3 7a n dD ’ =
0.895), and rs16928751 (r
2 = 0.838 and D’ = 1.0) [44].
None of the four variants associating with CVD risk
have any known or obvious functional role. The
rs16928751 is located in exon 7, but does not alter
amino acid sequence, whereas both rs11061937 and
rs1058322 are located in introns. Rs10848554 is located
in the 5’ promoter region and could potentially have
some regulatory role in transcription regulation.
In the present study, the individuals homozygous for
the rare minor alleles of two intronic SNPs, rs11061946
(T) and rs11061973 (A), had increased risk of conversion
from IGT to T2DM. These SNPs are in high LD (r
2 =
0.674) and the individuals with the rs11061946 TT geno-
type were also the only ones who had the rs11061973 AA
genotype. These results are in line with some of the ear-
lier studies indicating association between other ADI-
POR2 SNPs and the incidence of T2DM [18,20,21] even
though a number of studies have failed to replicate asso-
ciation between ADIPOR2 SNPs and T2DM [27-29].
Both rs11061946 and rs11061973 are intronic SNPs, have
no known functional significance, and may therefore be
merely markers in LD with a true causal variant. More-
over, our results should be interpreted with caution,
since the number of individuals homozygous for the
minor alleles was low (n = 5), and genotype differences in
T2DM risk were not observed when the dominant inheri-
tance model was applied. The SNP rs1044471, located in
the 3’ untranslated region, did not associate with T2DM
risk in the DPS population. Previously this SNP has been
associated with T2DM in Amish [21], but not in Korean
[28] population.
The regulation of the expression of ADIPOR1 and
ADIPOR2 is currently poorly understood as findings in
Table 5 Hazard ratios for the significant association between ADIPOR2 SNPs and the development of T2DM during
follow-up of median 7 years
HR (95% CI), p/q
a HR (95% CI), p/q
b
rs11061946 CC (428) 1 1
CT (49) 0.706 (0.412- 1.211), 0.206/0.517 0.872 (0.536- 1.417), 0.579/0.596
TT (5) 5.538 (2.014- 15.226), 0.001/0.369
rs11061973 GG (401) 1 1
GA (76) 0.951 (0.636- 1.423), 0.808/0.657 1.061 (0.724- 1.557), 0.761/0.657
AA (5) 5.683 (2.066- 15.636), 0.001/0.369
All analyses were adjusted for CVD at baseline, age, sex, baseline waist circumference, baseline total to HDL cholesterol ratio, smoking status, systolic blood
pressure and study group; Correction for multiple hypothesis testing in single SNP analyses was performed by using FDR, denoted as q-value;
aAdditive
inheritance model for single SNP analyses;
bDominant inheritance model for single SNP analyses.
Figure 2 The mRNA expression of ADIPOR2 in PBMCs of
Genobin study participants according to rs1058322. Values are
means ± SEM. Dominant inheritance model, adjusted for age, sex
and baseline BMI.
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Page 7 of 11different tissues, species and physiological conditions are
controversial. Several human studies have observed
decreased AT expression of either or both receptors in
obesity [17,45]. In muscle, the expression levels of ADI-
POR1 and ADIPOR2 correlated positively with obesity,
glucose and insulin levels and insulin resistance [46].
On the contrary, the expression levels were decreased in
nondiabetic individuals with a family history of T2DM
when compared with those without family history [15].
In liver, the mRNA levels of ADIPOR2 were increased
[47] or decreased [48] in NASH, and the mRNA levels
of both receptors were increased in insulin resistance
[49]. Finally the expression of ADIPOR1 and ADIPOR2
at protein level was decreased in monocytes of indivi-
duals with coronary artery disease, but no difference
was observed at the mRNA level [50].
These partly controversial results suggest that ADI-
POR1 and ADIPOR2 expression may be regulated in a
tissue-specific manner, and may be partly explained by
genetic factors. Wang et al. found allele-specific differ-
ences in expression levels in individuals heterozygous
for the ADIPOR1 SNP rs1139646 [51], whereas Halvat-
siotis et al. observed that the ADIPOR2 variant rs767870
associated both with CVD and altered ADIPOR2 protein
expression levels in peripheral monocytes [26]. Soccio et
al. reported that ADIPOR1 SNPs predisposing to CAD
were also associated with low ADIPOR1 expression
levels in PBMCs and AT biopsies [52]. Interestingly, we
found different expression levels according to rs1058322
genotype in middle aged Finnish individuals with
impaired glucose metabolism and features of the meta-
bolic syndrome who were participating in another study.
Individuals carrying the T allele, who had increased risk
of CVD in the DPS population, demonstrated decreased
mRNA expression levels in the PBMC samples of the
Genobin study participants [53].
The mechanisms by which ADIPOR2 variants might
influence the risk of CVD and T2DM are currently
hypothetical. The recent advances in human genetics
have indicated that the gene variants underlying com-
plex diseases usually have subtle effects on phenotype,
often through temporal and spatial alterations in gene
expression [54]. In addition, complex diseases and quan-
titative traits are largely affected by environmental fac-
tors that may interact with genetic factors. Moreover,
genetic variants within the same gene locus or within
different loci may have additive or epistatic effects on
each other. These phenomena which are still poorly
understood may explain to some extent the inconsistent
findings in different study populations. Nevertheless,
PBMCs are important players in inflammation, which is
closely connected to both CVD and T2DM. Monocytes
and macrophages are the target cells of the anti-
atherogenic and anti-inflammatory effects of adiponectin
[2,55] and SNPs affecting tissue-specific expression of
ADIPOR2 may disturb these interactions directly.
The anti-atherogentic effects of adiponectin are well
documented in vitro and in animal models [6,7,11,55] and
circulating adiponectin levels are decreased in CAD
patients [10]. Whether low adiponectin levels are asso-
ciated with future risk of cardiovascular events is, however,
currently unclear [56]. In a subgroup of DPS participants,
we observed a trend for lower CVD risk in those with
higher than median serum adiponectin levels compared
with those whose adiponectin levels were lower than med-
ian. However, since the number of individuals with base-
line measurements of circulating adiponectin data was
low, this result should be interpreted with caution.
The limitation of this study is the fairly small size of
the DPS population for genetic association studies. This
may weaken the statistical power to find true associa-
tions or increase the chance of false positive findings.
The associations between rs10848554, rs11061937,
rs1058322, rs16928751 and the risk of CVD were signifi-
cant when considering the combinations of p- and q-
values (p < 0.05 and q < 0.150). However, although the
p-values were significant the genotype associations with
T2DM risk and mRNA expression levels the q-values
were high and the results should be interpreted with
caution. Concerning the expression studies, we mea-
sured ADIPOR2 expression only at mRNA level and it is
not known if this difference is reflected in expression at
protein level.
The major strength of this study is the longitudinal
study design with a lifestyle intervention, which may
increase the power to find true associations compared
with cross-sectional settings. In addition, our study popu-
lations consisted of homogeneous group of individuals
with impaired glucose metabolism, and therefore increased
risk of both T2DM and CVD. Moreover, the risk of false
association is further decreased by the accurate selection
and phenotyping of the DPS participants. In addition we
used the tagSNP selection approach to capture maximal
amount of common genetic variation in the ADIPOR2
locus with minimal set of informative SNPs.
Conclusions
In conclusion, the results of the present study are in
agreement with previous findings suggesting a role for
ADIPOR2 gene in susceptibility to CVD and T2DM,
possibly through independent genetic effects. Different
variants in the ADIPOR2 locus may act independently
or in concert to induce subtle and possibly tissue speci-
fic alterations in gene expression. The observation of
allele-specific differences according to rs1058322 variant
in mRNA expression levels further support this view.
Siitonen et al. Cardiovascular Diabetology 2011, 10:83
http://www.cardiab.com/content/10/1/83
Page 8 of 11Acknowledgements
This study has been financially supported by grants from the Academy of
Finland (117844 and 40758, 211497, and 118590 (MU); The EVO funding of
the Kuopio University Hospital from Ministry of Health and Social Affairs
(5254), Finnish Funding Agency for Technology and Innovation (40058/07),
Nordic Centre of Excellence on ‘Systems biology in controlled dietary
interventions and cohort studies, SYSDIET (070014), The Finnish Diabetes
Research Foundation, Yrjö Jahnsson Foundation (56358), Sigrid Juselius
Foundation, Doctoral Program in Molecular Medicine at the University of
Eastern Finland, TEKES 70103/06 and 40058/07 and InterAct.
Author details
1Department of Clinical Nutrition and Food and Health Research Centre,
Institute of Public Health and Clinical Nutrition, University of Eastern Finland,
Kuopio, Finland.
2Department of Health Promotion and Chronic Disease
Prevention, National Institute for Health and Welfare, Helsinki, Finland.
3Department of Public Health, University of Helsinki, Helsinki, Finland.
4Institute of Medicine, Clinical Medicine, Kuopio University Hospital, Kuopio,
Finland.
5Folkhalsan Research Centre, Helsinki, Finland.
6Department of
General Practice and Primary Health Care, University of Helsinki, Helsinki,
Finland.
7Vasa Central Hospital, Vasa, Finland.
8Unit of General Practice,
Helsinki University Central Hospital, Helsinki, Finland.
9Diabetes Centre,
Finnish Diabetes Association, Tampere, Finland.
10Science Centre, Pirkanmaa
Hospital District, Tampere University Hospital, Tampere, Finland.
11Institute of
Health Sciences, University of Oulu, Oulu, Finland.
12Unit of General Practice,
Oulu University Hospital, Oulu, Finland.
13Health Centre of Oulu, Oulu
Finland.
14South Ostrobothnia Central Hospital, Seinäjoki, Finland.
15Department of Preventive and Clinical Medicine, Danube-Universität Krems,
Krems, Austria.
16Research Unit, Kuopio University Hospital, Kuopio, Finland.
Authors’ contributions
NS participated in designing the genetic studies, performed the genotyping
and statistical analyses, and drafted the manuscript. LP participated in
designing the genetic studies and writing the manuscript. MK and US
contributed to the design of the Genobin study and writing the manuscript.
JL, JGE, PIP and SKK contributed to the DPS study design and coordination
and revised the manuscript. JT and MU are the principle investigators of the
DPS study and participated in writing the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 10 July 2011 Accepted: 24 September 2011
Published: 24 September 2011
References
1. Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and
metabolic disease. Nat Rev Immunol 2011, 11(2):85-97.
2. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M,
Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y,
Yamashita S, Funahashi T, Matsuzawa Y: Adipocyte-derived plasma
protein, adiponectin, suppresses lipid accumulation and class A
scavenger receptor expression in human monocyte-derived
macrophages. Circulation 2001, 103(8):1057-1063.
3. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y,
Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M,
Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P,
Kimura S, Nagai R, Kadowaki T: Globular adiponectin protected ob/ob
mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol
Chem 2003, 278(4):2461-2468.
4. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T,
Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O,
Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K,
Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived
hormone adiponectin reverses insulin resistance associated with both
lipoatrophy and obesity. Nat Med 2001, 7(8):941-946.
5. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S,
Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P,
Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T: Adiponectin stimulates
glucose utilization and fatty-acid oxidation by activating AMP-activated
protein kinase. Nat Med 2002, 8(11):1288-1295.
6. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K,
Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T,
Matsuzawa Y: Novel modulator for endothelial adhesion molecules:
adipocyte-derived plasma protein adiponectin. Circulation 1999,
100(25):2473-2476.
7. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M,
Hotta K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M,
Ohmoto Y, Funahashi T, Matsuzawa Y: Adipocyte-derived plasma protein
adiponectin acts as a platelet-derived growth factor-BB-binding protein
and regulates growth factor-induced common postreceptor signal in
vascular smooth muscle cell. Circulation 2002, 105(24):2893-2898.
8. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE,
Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close
association with insulin resistance and hyperinsulinemia. J Clin Endocrinol
Metab 2001, 86(5):1930-1935.
9. Matsubara M, Maruoka S, Katayose S: Decreased plasma adiponectin
concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002,
87(6):2764-2769.
10. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N,
Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T,
Matsuzawa Y, Osaka CAD Study Group. Coronary artery disease: Association
of hypoadiponectinemia with coronary artery disease in men. Arterioscler
Thromb Vasc Biol 2003, 23(1):85-89.
11. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin
stimulates production of nitric oxide in vascular endothelial cells. J Biol
Chem 2003, 278(45):45021-45026.
12. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T,
Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S,
Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K,
Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T: Cloning of
adiponectin receptors that mediate antidiabetic metabolic effects.
Nature 2003, 423(6941):762-769.
13. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-
Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A,
Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T,
Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R,
Ueki K, Kadowaki T: Targeted disruption of AdipoR1 and AdipoR2 causes
abrogation of adiponectin binding and metabolic actions. Nat Med 2007,
13(3):332-339.
14. Bjursell M, Ahnmark A, Bohlooly-Y M, William-Olsson L, Rhedin M, Peng XR,
Ploj K, Gerdin AK, Arnerup G, Elmgren A, Berg AL, Oscarsson J, Linden D:
Opposing effects of adiponectin receptors 1 and 2 on energy
metabolism. Diabetes 2007, 56(3):583-593.
15. Civitarese AE, Jenkinson CP, Richardson D, Bajaj M, Cusi K, Kashyap S,
Berria R, Belfort R, DeFronzo RA, Mandarino LJ, Ravussin E: Adiponectin
receptors gene expression and insulin sensitivity in non-diabetic
Mexican Americans with or without a family history of Type 2 diabetes.
Diabetologia 2004, 47(5):816-820.
16. Staiger H, Kaltenbach S, Staiger K, Stefan N, Fritsche A, Guirguis A, Peterfi C,
Weisser M, Machicao F, Stumvoll M, Haring HU: Expression of adiponectin
receptor mRNA in human skeletal muscle cells is related to in vivo
parameters of glucose and lipid metabolism. Diabetes 2004,
53(9):2195-2201.
17. Morinigo R, Musri M, Vidal J, Casamitjana R, Delgado S, Lacy AM, Ayuso C,
Gomis R, Corominola H: Intra-abdominal fat adiponectin receptors
expression and cardiovascular metabolic risk factors in obesity and
diabetes. Obes Surg 2006, 16(6):745-751.
18. Potapov VA, Chistiakov DA, Dubinina A, Shamkhalova MS, Shestakova MV,
Nosikov VV: Adiponectin and adiponectin receptor gene variants in
relation to type 2 diabetes and insulin resistance-related phenotypes.
Rev Diabet Stud 2008, 5(1):28-37.
19. Rasmussen-Torvik LJ, Pankow JS, Jacobs DR Jr, Steinberger J, Moran A,
Sinaiko AR: The association of SNPs in ADIPOQ, ADIPOR1, and ADIPOR2
with insulin sensitivity in a cohort of adolescents and their parents. Hum
Genet 2009, 125(1):21-28.
20. Vaxillaire M, Dechaume A, Vasseur-Delannoy V, Lahmidi S, Vatin V,
Lepretre F, Boutin P, Hercberg S, Charpentier G, Dina C, Froguel P: Genetic
Analysis of ADIPOR1 and ADIPOR2 Candidate Polymorphisms for Type 2
Diabetes in the Caucasian Population. Diabetes 2006, 55(3):856-861.
Siitonen et al. Cardiovascular Diabetology 2011, 10:83
http://www.cardiab.com/content/10/1/83
Page 9 of 1121. Damcott CM, Ott SH, Pollin TI, Reinhart LJ, Wang J, O’connell JR,
Mitchell BD, Shuldiner AR: Genetic variation in adiponectin receptor 1
and adiponectin receptor 2 is associated with type 2 diabetes in the Old
Order Amish. Diabetes 2005, 54(7):2245-2250.
22. Broedl UC, Lehrke M, Fleischer-Brielmaier E, Tietz AB, Nagel JM, Goke B,
Lohse P, Parhofer KG: Genetic variants of adiponectin receptor 2 are
associated with increased adiponectin levels and decreased triglyceride/
VLDL levels in patients with metabolic syndrome. Cardiovasc Diabetol
2006, 5:11.
23. Richardson DK, Schneider J, Fourcaudot MJ, Rodriguez LM, Arya R, Dyer TD,
Almasy L, Blangero J, Stern MP, Defronzo RA, Duggirala R, Jenkinson CP:
Association between variants in the genes for adiponectin and its
receptors with insulin resistance syndrome (IRS)-related phenotypes in
Mexican Americans. Diabetologia 2006, 49(10):2317-2328.
24. Kotronen A, Yki-Jarvinen H, Aminoff A, Bergholm R, Pietilainen KH,
Westerbacka J, Talmud PJ, Humphries SE, Hamsten A, Isomaa B, Groop L,
Orho-Melander M, Ehrenborg E, Fisher RM: Genetic variation in the
ADIPOR2 gene is associated with liver fat content and its surrogate
markers in three independent cohorts. Eur J Endocrinol 2009,
160(4):593-602.
25. Lopez-Bermejo A, Botas-Cervero P, Ortega-Delgado F, Delgado E, Garcia-
Gil MM, Funahashi T, Ricart W, Fernandez-Real JM: Association of ADIPOR2
with liver function tests in type 2 diabetic subjects. Obesity (Silver Spring)
2008, 16(10):2308-2313.
26. Halvatsiotis I, Tsiotra PC, Ikonomidis I, Kollias A, Mitrou P, Maratou E,
Boutati E, Lekakis J, Dimitriadis G, Economopoulos T, Kremastinos DT,
Raptis SA: Genetic variation in the adiponectin receptor 2 (ADIPOR2)
gene is associated with coronary artery disease and increased ADIPOR2
expression in peripheral monocytes. Cardiovasc Diabetol 2010, 9:10.
27. Qi L, Doria A, Giorgi E, Hu FB: Variations in adiponectin receptor genes
and susceptibility to type 2 diabetes in women: a tagging-single
nucleotide polymorphism haplotype analysis. Diabetes 2007,
56(6):1586-1591.
28. Kim JT, Kim Y, Cho YM, Koo BK, Lee EK, Shin HD, Jang HC, Choi JW, Oh B,
Park KS: Polymorphisms of ADIPOR1 and ADIPOR2 are associated with
phenotypes of type 2 diabetes in Koreans. Clin Endocrinol (Oxf) 2009,
70(1):66-74.
29. Collins SC, Luan J, Thompson AJ, Daly A, Semple RK, O’Rahilly S,
Wareham NJ, Barroso I: Adiponectin receptor genes: mutation screening
in syndromes of insulin resistance and association studies for type 2
diabetes and metabolic traits in UK populations. Diabetologia 2007,
50(3):555-562.
30. Ferguson JF, Phillips CM, Tierney AC, Perez-Martinez P, Defoort C, Helal O,
Lairon D, Planells R, Shaw DI, Lovegrove JA, Gjelstad IM, Drevon CA,
Blaak EE, Saris WH, Leszczynska-Golabek I, Kiec-Wilk B, Riserus U, Karlstrom B,
Miranda JL, Roche HM: Gene-nutrient interactions in the metabolic
syndrome: single nucleotide polymorphisms in ADIPOQ and ADIPOR1
interact with plasma saturated fatty acids to modulate insulin resistance.
Am J Clin Nutr 2010, 91(3):794-801.
31. Stefan N, Machicao F, Staiger H, Machann J, Schick F, Tschritter O, Spieth C,
Weigert C, Fritsche A, Stumvoll M, Haring HU: Polymorphisms in the gene
encoding adiponectin receptor 1 are associated with insulin resistance
and high liver fat. Diabetologia 2005, 48(11):2282-2291.
32. World Health Organization Expert Committee: Diabetes Mellitus. Technical
Report Series. 1985, 742.
33. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-
Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M,
Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group:
Prevention of type 2 diabetes mellitus by changes in lifestyle among
subjects with impaired glucose tolerance. N Engl J Med 2001,
344(18):1343-1350.
34. Eriksson J, Lindstrom J, Valle T, Aunola S, Hamalainen H, Ilanne-Parikka P,
Keinanen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A,
Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A,
Viljanen T, Uusitupa M, Tuomilehto J: Prevention of Type II diabetes in
subjects with impaired glucose tolerance: the Diabetes Prevention Study
(DPS) in Finland. Study design and 1-year interim report on the
feasibility of the lifestyle intervention programme. Diabetologia 1999,
42(7):793-801.
35. Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J,
Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study Group: The
Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-
year results on diet and physical activity. Diabetes Care 2003,
26(12):3230-3236.
36. Uusitupa M, Peltonen M, Lindstrom J, Aunola S, Ilanne-Parikka P, Keinanen-
Kiukaanniemi S, Valle TT, Eriksson JG, Tuomilehto J, Finnish Diabetes
Prevention Study Group: Ten-year mortality and cardiovascular morbidity
in the Finnish Diabetes Prevention Study-secondary analysis of the
randomized trial. PLoS One 2009, 4(5):e5656.
37. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults: Executive Summary of the Third Report of the
National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
38. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA,
Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F:
Diagnosis and management of the metabolic syndrome: an American
Heart Association/National Heart, Lung, and Blood Institute scientific
statement. Curr Opin Cardiol 2006, 21(1):1-6.
39. International HapMap Consortium: The International HapMap Project.
Nature 2003, 426(6968):789-796.
40. de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, Altshuler D: Efficiency
and power in genetic association studies. Nat Genet 2005,
37(11):1217-1223.
41. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of
LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
42. Storey JD, Tibshirani R: Statistical significance for genomewide studies.
Proc Natl Acad Sci USA 2003, 100(16):9440-9445.
43. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K,
Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M,
Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M,
Tuomilehto J, Finnish Diabetes Prevention Study Group: Sustained
reduction in the incidence of type 2 diabetes by lifestyle intervention:
follow-up of the Finnish Diabetes Prevention Study. Lancet 2006,
368(9548):1673-1679.
44. Thorisson GA, Smith AV, Krishnan L, Stein LD: The International HapMap
Project Web site. Genome Res 2005, 15(11):1592-1593.
45. Nannipieri M, Bonotti A, Anselmino M, Cecchetti F, Madec S, Mancini E,
Baldi S, Santini F, Pinchera A, Rossi M, Ferrannini E: Pattern of expression
of adiponectin receptors in human adipose tissue depots and its
relation to the metabolic state. Int J Obes (Lond) 2007, 31(12):1843-1848.
46. Bluher M, Bullen JW Jr, Lee JH, Kralisch S, Fasshauer M, Kloting N,
Niebauer J, Schon MR, Williams CJ, Mantzoros CS: Circulating adiponectin
and expression of adiponectin receptors in human skeletal muscle:
associations with metabolic parameters and insulin resistance and
regulation by physical training. J Clin Endocrinol Metab 2006,
91(6):2310-2316.
47. Nannipieri M, Cecchetti F, Anselmino M, Mancini E, Marchetti G, Bonotti A,
Baldi S, Solito B, Giannetti M, Pinchera A, Santini F, Ferrannini E: Pattern of
expression of adiponectin receptors in human liver and its relation to
nonalcoholic steatohepatitis. Obes Surg 2009, 19(4):467-474.
48. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F,
Ebenbichler CF, Patsch JR, Tilg H: Adiponectin and its receptors in non-
alcoholic steatohepatitis. Gut 2005, 54(1):117-121.
49. Felder TK, Hahne P, Soyal SM, Miller K, Hoffinger H, Oberkofler H,
Krempler F, Patsch W: Hepatic adiponectin receptors (ADIPOR) 1 and 2
mRNA and their relation to insulin resistance in obese humans. Int J
Obes (Lond) 2010, 34(5):846-851.
50. Kollias A, Tsiotra PC, Ikonomidis I, Maratou E, Mitrou P, Kyriazi E, Boutati E,
Lekakis J, Economopoulos T, Kremastinos DT, Dimitriadis G, Raptis SA:
Adiponectin levels and expression of adiponectin receptors in isolated
monocytes from overweight patients with coronary artery disease.
Cardiovasc Diabetol 2011, 10:14.
51. Wang H, Zhang H, Jia Y, Zhang Z, Craig R, Wang X, Elbein SC: Adiponectin
Receptor 1 Gene (ADIPOR1) as a Candidate for Type 2 Diabetes and
Insulin Resistance. Diabetes 2004, 53(8):2132-2136.
52. Soccio T, Zhang YY, Bacci S, Mlynarski W, Placha G, Raggio G, Di Paola R,
Marucci A, Johnstone MT, Gervino EV, Abumrad NA, Klein S, Trischitta V,
Doria A: Common haplotypes at the adiponectin receptor 1 (ADIPOR1)
locus are associated with increased risk of coronary artery disease in
type 2 diabetes. Diabetes 2006, 55(10):2763-2770.
Siitonen et al. Cardiovascular Diabetology 2011, 10:83
http://www.cardiab.com/content/10/1/83
Page 10 of 1153. Mager U, Kolehmainen M, de Mello VD, Schwab U, Laaksonen DE,
Rauramaa R, Gylling H, Atalay M, Pulkkinen L, Uusitupa M: Expression of
ghrelin gene in peripheral blood mononuclear cells and plasma ghrelin
concentrations in patients with metabolic syndrome. Eur J Endocrinol
2008, 158(4):499-510.
54. Hardy J, Singleton A: Genomewide association studies and human
disease. N Engl J Med 2009, 360(17):1759-1768.
55. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K,
Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T,
Matsuzawa Y: Adiponectin reduces atherosclerosis in apolipoprotein E-
deficient mice. Circulation 2002, 106(22):2767-2770.
56. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM,
Danesh J, Whincup PH: Adiponectin and coronary heart disease: a
prospective study and meta-analysis. Circulation 2006, 114(7):623-629.
doi:10.1186/1475-2840-10-83
Cite this article as: Siitonen et al.: Association of ADIPOR2 gene variants
with cardiovascular disease and type 2 diabetes risk in individuals with
impaired glucose tolerance: the Finnish Diabetes Prevention Study.
Cardiovascular Diabetology 2011 10:83.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Siitonen et al. Cardiovascular Diabetology 2011, 10:83
http://www.cardiab.com/content/10/1/83
Page 11 of 11